Immunity conferred by Aro− salmonella live vaccines

Hormaeche, Carlos E.; Joysey, H S; Desilva, Leel; Izhar, Mateen; Stocker, B. A. D.

doi:10.1016/0882-4010(91)90075-l

Cited by 70 publications

(56 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More recently, Matulova et al (48) showed that S. Typhimurium and S. Enteritidis live vaccines with SPI-1 mutations can protect chickens against challenge with either serovar. However, our results are congruent with those of Hormaeche et al (49), who showed that the S. Typhimurium aroA vaccine SL3261 conferred protection against 10,000 LD 50 of S. Typhimurium but no protection against S. Enteritidis. Taken together, the crossprotection data suggest that live attenuated S. Typhimurium vaccines can protect against challenge with S. Typhimurium but that protection against other serovars is variable.…”

Section: Discussionsupporting

confidence: 82%

Refined Live Attenuated Salmonella enterica Serovar Typhimurium and Enteritidis Vaccines Mediate Homologous and Heterologous Serogroup Protection in Mice

et al. 2015

View full text Add to dashboard Cite

Invasive nontyphoidal Salmonella (NTS) infections constitute a major health problem among infants and toddlers in sub-Saharan Africa; these infections also occur in infants and the elderly in developed countries. We genetically engineered a Salmonella enterica serovar Typhimurium strain of multilocus sequence type 313, the predominant genotype circulating in sub-Saharan Africa. We evaluated the capacities of S. Typhimurium and Salmonella enterica serovar Enteritidis ⌬guaBA ⌬clpX live oral vaccines to protect mice against a highly lethal challenge dose of the homologous serovar and determined protection against other group B and D serovars circulating in sub-Saharan Africa. The vaccines S. Typhimurium CVD 1931 and S. Enteritidis CVD 1944 were immunogenic and protected BALB/c mice against 10,000 50% lethal doses (LD 50 ) of S. Typhimurium or S. Enteritidis, respectively. S. Typhimurium CVD 1931 protected mice against the group B serovar Salmonella enterica serovar Stanleyville (91% vaccine efficacy), and S. Enteritidis CVD 1944 protected mice against the group D serovar Salmonella enterica serovar Dublin (85% vaccine efficacy). High rates of survival were observed when mice were infected 12 weeks postimmunization, indicating that the vaccines elicited long-lived protective immunity. Whereas CVD 1931 did not protect against S. Enteritidis R11, CVD 1944 did mediate protection against S. Typhimurium D65 (81% efficacy). These findings suggest that a bivalent (S. Typhimurium and S. Enteritidis) vaccine would provide broad protection against the majority of invasive NTS infections in sub-Saharan Africa. N on-typhoidal Salmonella (NTS) is a leading cause of bacterial bloodstream infections in febrile children and immunocompromised individuals in sub-Saharan Africa and has been associated with a high case fatality rate of 20 to 25% (1). Although severe malarial anemia and human immunodeficiency virus (HIV) are important risk factors for invasive NTS infection, the disease is also common in low-HIV-prevalence areas (1-4).There are Ͼ2,500 Salmonella serovars that can be differentiated on the basis of the O polysaccharide (OPS) antigens of their lipopolysaccharide (LPS) and their H flagellum antigens, using the Kauffman-White typing scheme (5). For example, Salmonella enterica serovar Typhimurium has O antigens 1, 4, 12, and occasionally 5. Epitope 12 is formed by trisaccharide repeats of mannose, rhamnose, and galactose; glucosylation of the galactose residue forms epitope 1. An abequose linked to each mannose defines it as a serovar within group B and constitutes the immunodominant O4 epitope; epitope 5 results from a phage conversion that introduces an O-acetyl moiety on the abequose. S. Typhimurium also has separate H antigens, i (phase 1) and 1 and 2 (phase 2), expressed alternatively via a process called phase variation. In contrast, Salmonella enterica serovar Enteritidis has O antigen epitope 9, which identifies it as a member of group D. Epitope 9 is formed by a tyvelose residue that is linked to the mannose of the ...

show abstract

Section: Discussionsupporting

confidence: 82%

Refined Live Attenuated Salmonella enterica Serovar Typhimurium and Enteritidis Vaccines Mediate Homologous and Heterologous Serogroup Protection in Mice

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In C57BL/6 mice, the efficacious immune response against attenuated S. typhimurium strains gives rise to protection against subsequent oral challenge with doses of wild-type S. typhimurium that are fatal for nonvaccinated animals (16 ( Table I). Vaccination with the aroA Ϫ strain induced protection in Ig ϩ/ϩ mice and some of these mice survived even challenge infection with 2 ϫ 10 9 virulent bacteria.…”

Section: Resultsmentioning

confidence: 99%

“…Depending on the degree of bacterial attenuation, Nramp1 s mice control infection and are protected against reinfection with wild-type S. typhimurium (15)(16)(17)(18). Experiments with gene-deficient mice demonstrated that control of primary infection with an attenuated S. typhimurium strain (aroA Ϫ ) strictly depends on CD4 ϩ T lymphocytes (19).…”

mentioning

confidence: 99%

Cutting Edge: Role of B Lymphocytes in Protective Immunity AgainstSalmonella typhimuriumInfection

Mittrücker

Raupach

Köhler

et al. 2000

The Journal of Immunology

180

154

View full text Add to dashboard Cite

Infection of mice with Salmonella typhimurium gives rise to a disease similar to human typhoid fever caused by S. typhi. Since S. typhimurium is a facultative intracellular bacterium, the requirement of B cells in the immune response against S. typhimurium is a longstanding matter of debate. By infecting mice on a susceptible background and deficient in B cells (Igμ−/− mice) with different strains of S. typhimurium, we could for the first time formally clarify the role of B cells in the response against S. typhimurium. Compared with Igμ+/+ mice, LD50 values in Igμ−/− mice were reduced during primary, and particularly secondary, oral infection with virulent S. typhimurium. After systemic infection, Igμ−/− mice cleared attenuated aroA− S. typhimurium, but vaccine-induced protection against systemic infection with virulent S. typhimurium involved both B cell-dependent and -independent effector mechanisms. Thus, B cell-mediated immunity plays a distinct role in control of S. typhimurium in susceptible mice.

show abstract

“…In a murine model, anti-lipid A monoclonal [7] or anti-idiotype antibodies [13] protected mice against a lethal challenge with rough LPS. However, it was demonstrated that by using direct passive transfer of anti-LPS antibodies [20,21,28,29,37], LPS alone cannot fully account for the specificity of protection by antibodies. The specificity of cross-protection was previously studied [19], using Typhimurium, Enteritidis and Dublin for vaccination and challenge, with variants that differed in the main LPS antigen (0-4 or 0-9).…”

Section: Discussionmentioning

confidence: 99%

Cross-protection of Salmonella abortusovis, S. choleraesuis, S. dublin and S. gallinarum in mice induced by S. abortusovis and S. gallinarum: bacteriology and humoral immune response

Bernard¹,

Boivin²,

Menanteau³

et al. 2002

Vet. Res.

View full text Add to dashboard Cite

Immunity conferred by Aro− salmonella live vaccines

Cited by 70 publications

References 34 publications

Refined Live Attenuated Salmonella enterica Serovar Typhimurium and Enteritidis Vaccines Mediate Homologous and Heterologous Serogroup Protection in Mice

Refined Live Attenuated Salmonella enterica Serovar Typhimurium and Enteritidis Vaccines Mediate Homologous and Heterologous Serogroup Protection in Mice

Cutting Edge: Role of B Lymphocytes in Protective Immunity AgainstSalmonella typhimuriumInfection

Cross-protection of Salmonella abortusovis, S. choleraesuis, S. dublin and S. gallinarum in mice induced by S. abortusovis and S. gallinarum: bacteriology and humoral immune response

Contact Info

Product

Resources

About